Thyroid Neoplasms

• EMA approval · 2026-08-05
  EMA Authorised: Caprelsa (vandetanib) — Esteve Pharmaceuticals, S.A.

  Caprelsa (vandetanib) has been authorised by the EMA for thyroid neoplasms.

• EMA approval · 2026-07-22
  EMA Authorised: Cometriq (cabozantinib) — Ipsen Pharma

  Cometriq (cabozantinib) has been authorised in the EU for therapeutic use in thyroid neoplasms by Ipsen Pharma.

• EMA approval · 2026-07-10
  EMA Authorised: Cometriq (cabozantinib) — Ipsen Pharma

  Cometriq (cabozantinib) has been authorised in the European Union for thyroid neoplasms.

• EMA approval · 2026-07-03
  EMA Authorised: Retsevmo (selpercatinib) — Eli Lilly Nederland B.V.

  Authorization of Retsevmo (selpercatinib) by EMA for use in non-small cell lung cancer and thyroid neoplasms.

• EMA approval · 2026-03-26
  EMA Authorised: Lenvima (lenvatinib mesilate) — Eisai GmbH

  EMA authorised Lenvima (lenvatinib mesilate) by Eisai GmbH for thyroid neoplasms, under accelerated assessment, with a decision dated 26 Mar…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA approval · 2026-02-27
  EMA Authorised: Cometriq (cabozantinib) — Ipsen Pharma

  The European Medicines Agency authorised Cometriq (cabozantinib) for thyroid neoplasms, with Ipsen Pharma as the marketing authorisation hol…

• EMA approval · 2026-02-12
  EMA Authorised: Retsevmo (selpercatinib) — Eli Lilly Nederland B.V.

  The European Medicines Agency authorised Retsevmo (selpercatinib) for RET fusion-positive cancers in the EU, including non-small cell lung c…

• EMA approval · 2025-12-08
  EMA Authorised: Caprelsa (vandetanib) — Sanofi B.V.

  The European Medicines Agency authorised Caprelsa (vandetanib) for thyroid neoplasms, including medullary thyroid carcinoma, with Sanofi B.V…

• EMA approval · 2025-02-19
  EMA Authorised: Thyrogen (thyrotropin alfa) — Sanofi B.V.

  The European Medicines Agency has authorised Thyrogen (thyrotropin alfa) for use in thyroid neoplasms. The marketing authorization holder is…